Beta Bionics receives FDA Warning Letter; quality remediation underway as PBP sales climb

Filed April 21, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 6, 2025 · ~2 min read

Key Changes

• high

  FDA issued Warning Letter in January 2026 citing deficiencies in Quality Management System, Medical Device Reporting, and Correction and Removals following June 2025 facility inspection. Company incurring remediation costs ($0.6M per quarter) for contractor support and quality system updates.

  MD&A: Regulatory Compliance verify on EDGAR →
• high

  Pharmacy benefit pathway (PBP) sales grew to 39% of revenue in Q1 2026 from 22% in Q1 2025, reflecting strategic shift toward channel with better long-term economics despite lower upfront revenue recognition.

  MD&A: Revenue Mix verify on EDGAR →
• medium

  Cash and investments declined to $239.5M at March 31, 2026 from $295.5M a year earlier, a $56M decrease driven by operating losses and growth investments. Management maintains liquidity guidance through first half of 2028.

  MD&A: Liquidity verify on EDGAR →